There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vincera Pharma (VINC) and Medios AG (MEDOF) with bullish sentiments.
Vincera Pharma (VINC)
In a report issued on March 24, Geulah Livshits from Chardan Capital reiterated a Buy rating on Vincera Pharma, with a price target of $33.00. The company’s shares closed last Tuesday at $18.93.
According to TipRanks.com, Livshits is a top 100 analyst with an average return of 71.3% and a 66.9% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Crispr Therapeutics AG, and Intellia Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vincera Pharma with a $33.00 average price target, implying a 75.6% upside from current levels. In a report issued on March 10, LifeSci Capital also maintained a Buy rating on the stock with a $33.00 price target.
See today’s analyst top recommended stocks >>
Medios AG (MEDOF)
In a report issued on April 6, Charlotte Friedrichs from Berenberg Bank maintained a Buy rating on Medios AG, with a price target of EUR46.00.
According to TipRanks.com, Friedrichs is ranked #1107 out of 7451 analysts.
Medios AG has an analyst consensus of Strong Buy, with a price target consensus of $57.51, which is a 2456.0% upside from current levels. In a report issued on March 31, Jefferies also maintained a Buy rating on the stock with a EUR50.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
